Harvard Bioscience Inc (HBIO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Harvard Bioscience Inc (HBIO) has a cash flow conversion efficiency ratio of -0.066x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-662.00K) by net assets ($10.05 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Harvard Bioscience Inc (HBIO) net asset quality to measure how much of total assets are equity-financed.
Harvard Bioscience Inc - Cash Flow Conversion Efficiency Trend (1999–2025)
This chart illustrates how Harvard Bioscience Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Harvard Bioscience Inc (HBIO) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
Harvard Bioscience Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Harvard Bioscience Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bowen Acquisition Corp Ordinary Shares
NASDAQ:BOWN
|
0.000x |
|
Scienjoy Holding Corp
NASDAQ:SJ
|
0.008x |
|
NSC Groupe SA
PA:ALNSC
|
-0.028x |
|
Hamilton Global Opportunities PLC
PA:ALHGO
|
-0.012x |
|
Bellway PLC
LSE:BWY
|
-0.001x |
|
Sangamo Therapeutics Inc
NASDAQ:SGMO
|
-4.565x |
|
Salee Industry Public Company Limited
BK:SALEE
|
0.023x |
|
GWR Group Ltd
AU:GWR
|
0.020x |
Annual Cash Flow Conversion Efficiency for Harvard Bioscience Inc (1999–2025)
The table below shows the annual cash flow conversion efficiency of Harvard Bioscience Inc from 1999 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Harvard Bioscience Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $13.73 Million | $6.73 Million | 0.490x | +2055.11% |
| 2024-12-31 | $63.34 Million | $1.44 Million | 0.023x | -88.16% |
| 2023-12-31 | $73.07 Million | $14.03 Million | 0.192x | +1103.48% |
| 2022-12-31 | $72.22 Million | $1.15 Million | 0.016x | +5.42% |
| 2021-12-31 | $83.40 Million | $1.26 Million | 0.015x | -87.56% |
| 2020-12-31 | $76.68 Million | $9.33 Million | 0.122x | +23.54% |
| 2019-12-31 | $81.69 Million | $8.05 Million | 0.099x | +245.36% |
| 2018-12-31 | $82.18 Million | $2.34 Million | 0.029x | +118.30% |
| 2017-12-31 | $80.90 Million | $1.06 Million | 0.013x | -82.48% |
| 2016-12-31 | $72.20 Million | $5.38 Million | 0.075x | +720.68% |
| 2015-12-31 | $77.60 Million | $705.00K | 0.009x | -80.07% |
| 2014-12-31 | $95.47 Million | $4.35 Million | 0.046x | +6.06% |
| 2013-12-31 | $94.48 Million | $4.06 Million | 0.043x | -44.46% |
| 2012-12-31 | $104.21 Million | $8.06 Million | 0.077x | +16.38% |
| 2011-12-31 | $95.50 Million | $6.35 Million | 0.066x | -51.20% |
| 2010-12-31 | $90.25 Million | $12.29 Million | 0.136x | -37.91% |
| 2009-12-31 | $75.26 Million | $16.51 Million | 0.219x | +59.05% |
| 2008-12-31 | $66.72 Million | $9.20 Million | 0.138x | -15.18% |
| 2007-12-31 | $74.14 Million | $12.05 Million | 0.163x | +39.88% |
| 2006-12-31 | $71.88 Million | $8.36 Million | 0.116x | +53.09% |
| 2005-12-31 | $68.42 Million | $5.20 Million | 0.076x | -30.72% |
| 2004-12-31 | $104.36 Million | $11.44 Million | 0.110x | +434.44% |
| 2003-12-31 | $98.88 Million | $2.03 Million | 0.021x | +126.72% |
| 2002-12-31 | $88.38 Million | $799.46K | 0.009x | -85.24% |
| 2001-12-31 | $66.81 Million | $4.10 Million | 0.061x | +49.49% |
| 2000-12-31 | $52.33 Million | $2.15 Million | 0.041x | -88.81% |
| 1999-12-31 | $7.98 Million | $2.93 Million | 0.367x | -- |
About Harvard Bioscience Inc
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the Americas, Europe, the Middle East, Africa, Asia, and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrop… Read more